Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor

Allison A Gockley; David L Kolin; Christopher S Awtrey; Neal I Lindeman; Ursula A Matulonis; Panagiotis A Konstantinopoulos

doi:10.1016/j.ygyno.2018.05.028

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor

Gynecol Oncol. 2018 Aug;150(2):219-226. doi: 10.1016/j.ygyno.2018.05.028. Epub 2018 Jun 22.

Authors

Allison A Gockley¹, David L Kolin², Christopher S Awtrey³, Neal I Lindeman⁴, Ursula A Matulonis⁵, Panagiotis A Konstantinopoulos⁶

Affiliations

¹ Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
² Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
³ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Beth-Israel Deaconess Medical Center, Boston, MA 02130, USA.
⁴ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
⁶ Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: Panagiotis_konstantinopouos@dfci.harvard.edu.

PMID: 29937315
DOI: 10.1016/j.ygyno.2018.05.028

Abstract

A 42-year-old woman with a germline BRCA2 mutation and recurrent low-grade endometrioid endometrial adenocarcinoma experienced clinical and radiographic response to the poly (ADP ribose) polymerase (PARP) inhibitor, olaparib. Molecular and treatment factors are discussed.

Publication types

Case Reports

MeSH terms

Adult
BRCA2 Protein / genetics*
Carcinoma, Endometrioid / drug therapy*
Carcinoma, Endometrioid / enzymology
Carcinoma, Endometrioid / genetics
Carcinoma, Endometrioid / pathology
Endometrial Neoplasms / drug therapy*
Endometrial Neoplasms / enzymology
Endometrial Neoplasms / genetics
Endometrial Neoplasms / pathology
Female
Germ-Line Mutation*
Humans
Neoplasm Grading
Neoplasm Recurrence, Local / drug therapy
Neoplasm Recurrence, Local / enzymology
Neoplasm Recurrence, Local / genetics
Neoplasm Recurrence, Local / pathology
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*

Substances

BRCA2 Protein
BRCA2 protein, human
Poly(ADP-ribose) Polymerase Inhibitors